Ranjana Tavorath

Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.

Mary Srethapakdi, Franklin Liu, Ranjana Tavorath et al. · PubMed · 2000 · 127 citations

Life Sciences, Molecular Biology, Oncology +15

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors

Ramón Salazar, Rocio García‐Carbonero, Steven K. Libutti et al. · The Oncologist · 2017 · 77 citations · Full text

Medicine, Oncology, Pharmacology +13

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Anas Younes, Gilles Salles, Giovanni Martinelli et al. · Haematologica · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +14

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma

Anas Younes, Gilles Salles, R. Gregory Bociek et al. · Blood · 2014 · 16 citations

Medicine, Hematology, Oncology +11

A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP)

Philipp D. le Coutre, Oliver G. Ottmann, Norbert Gatterman et al. · Journal of Clinical Oncology · 2006 · 15 citations

Pharmacy, Pharmacology, Pharmacotherapy +13